Question

A patient with ulcerative colitis on mesalazine 2.4 g/day (MAYO score 1) in remission presents with bloody diarrhoea for the past 3–4 days. What is the next best step in management?

• A. Mesalazine suppository
• B. Increase dose to 4.8 g
• C. Budesonide
• D. Stool sample for infection

Hint:

Golden Rule in IBD Management: Every single patient presenting with an acute flare of Inflammatory Bowel Disease must be tested for Clostridioides difficile and other enteric pathogens BEFORE initiating high-dose steroids or escalating biological therapies.

Answer 1

The Correct Option is D

Concept:
A patient with an established diagnosis of Ulcerative Colitis (UC), who has been well-maintained in clinical remission on a standard maintenance dose of oral mesalazine, suddenly presents with an acute flare of symptoms, specifically new-onset bloody diarrhea.
The clinical dilemma involves deciding whether to immediately escalate their immunosuppressive IBD therapy or to first investigate alternative, rapidly treatable causes for the acute clinical deterioration.
Explanation:
• When a patient with previously stable Inflammatory Bowel Disease (IBD) presents with an acute exacerbation of symptoms (such as sudden bloody diarrhea, fever, or severe abdominal pain), the clinical presentation strongly mimics an acute IBD disease flare.

• However, it is a critical, universally accepted medical rule that before diagnosing a true autoimmune disease flare and blindly escalating the patient's immunosuppressive medications (which carry significant risks), the physician must absolutely rule out a superimposed enteric infection.

• Patients with IBD, particularly those on baseline immunomodulators or altered mucosal barriers, are at an exceedingly high risk for opportunistic gastrointestinal infections, most notoriously including Clostridioides difficile, as well as standard pathogens like Salmonella, Shigella, Campylobacter, and Cytomegalovirus (CMV).

• A superimposed C. difficile infection can present identically to a severe UC flare. If a clinician mistakenly treats an infectious colitis with high-dose steroids or escalates immunomodulators (Options A, B, or C) without treating the infection, the bacteria can rapidly proliferate, potentially leading to catastrophic toxic megacolon, bowel perforation, and death.

• Therefore, the absolute, mandatory "next best step" in the evaluation of any suspected acute IBD flare is to immediately obtain comprehensive stool studies (Option D), which must routinely include testing for C. difficile toxins and routine bacterial cultures.

• Only after an infectious etiology has been definitively ruled out via negative stool studies should the clinician proceed to escalate the IBD-specific therapy (such as increasing mesalazine doses or initiating corticosteroids).
Final Answer:
To ensure patient safety and avoid catastrophic complications, obtaining a stool sample to rule out a superimposed enteric infection must always precede the escalation of immunosuppressive therapy in an acute IBD flare.